A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322 · clinicaltrials.gov ↗
PHASE3
Phase
ENROLLING_BY_INVITATION
Status
760
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

UCB Biopharma SRL